What are the best treatments for Hereditary Hemorrhagic Telangiectasia?

Treatment for Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, focuses on managing bleeding, preventing complications from arteriovenous malformations (AVMs), and improving quality of life through a multidisciplinary approach. While there is no cure, current therapies range from local interventions like laser therapy for nosebleeds to systemic medications and surgical procedures to address internal vascular abnormalities.

What are the primary treatment strategies for HHT?

Management of Hereditary Hemorrhagic Telangiectasia is highly individualized based on the specific location and severity of vascular lesions. First-line treatments often focus on symptomatic control. For epistaxis (nosebleeds), which affects approximately 90% of patients, therapies include moisturizing nasal sprays, humidification, and, when necessary, laser photocoagulation or surgical procedures to cauterize bleeding vessels. For patients with significant internal AVMs, such as those in the lungs or liver, clinicians may utilize embolization—a minimally invasive procedure where specialized coils or plugs are placed to block abnormal blood flow.

Which medications are used to manage Hereditary Hemorrhagic Telangiectasia?

While no single drug cures Hereditary Hemorrhagic Telangiectasia, several medications are used to mitigate symptoms or reduce the frequency of bleeding:

• Bevacizumab (Avastin): Often used intravenously for patients with severe liver involvement or high-output heart failure to inhibit the growth of new, fragile blood vessels.


• Tranexamic acid: An antifibrinolytic agent that helps stabilize clots and is frequently prescribed for chronic, recurrent epistaxis or gastrointestinal bleeding.


• Estrogen/Progesterone therapy: Occasionally utilized in cases where bleeding is refractory to other treatments, though its use is debated and must be carefully weighed against side effects.


• Iron supplementation: Essential for managing chronic iron-deficiency anemia, which is a near-universal secondary complication of the condition.

How is a multidisciplinary care team structured for HHT?

Because Hereditary Hemorrhagic Telangiectasia is a systemic vascular disorder, care must be coordinated by a multidisciplinary team. The DiseaseMaps.org community, which includes 141 members living with this condition, emphasizes the importance of specialized centers. A typical care team should include:

• Interventional Radiologists: Essential for performing embolizations of pulmonary and hepatic AVMs.


• Otolaryngologists (ENTs): Specialists in managing severe, recurrent nasal bleeding.


• Hematologists: Experts in managing chronic anemia and coagulation issues.


• Genetic Counselors: To provide testing and family screening, as HHT follows an autosomal dominant inheritance pattern.


• Cardiologists/Pulmonologists: To monitor for pulmonary hypertension and high-output heart failure, which can occur as the disease progresses.

Are there emerging treatments for HHT?

Medical research into Hereditary Hemorrhagic Telangiectasia is rapidly evolving. Current clinical trials are investigating the efficacy of newer angiogenesis inhibitors and targeted therapies that address the underlying genetic pathways (specifically the TGF-beta signaling pathway). Researchers are also exploring the long-term safety of systemic anti-VEGF therapies to determine if earlier intervention can prevent the progression of visceral AVMs in asymptomatic patients.

Next steps

• Consult with a specialist at an HHT Center of Excellence to ensure your diagnostic imaging and treatment plan are up to date.


• Join the Hereditary Hemorrhagic Telangiectasia community on DiseaseMaps.org to connect with others who share your lived experience and to exchange practical management tips.


• Request a referral to a genetic counselor to discuss family screening, as first-degree relatives of individuals with HHT have a 50% risk of inheriting the condition.


• Maintain a detailed symptom log, especially regarding the frequency and duration of nosebleeds or signs of anemia, to share with your care team.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): HHT Overview.


• Orphanet: Rare Disease Database (ORPHA: 774).


• Cure HHT (HHT Foundation International): Clinical Guidelines and Patient Resources.


• OMIM (Online Mendelian Inheritance in Man): Entry #187300.